Comparative Efficacy, Safety, PK, and Immunogenicity Study

Summary

this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women with osteoporosis.

Timeline

Start

2023-04-05

Primary completion

2025-07-30

Completion

2025-12-30

Drugs

Indications